Specifically, the guidelines, while short of clinical trial evidence, recommend that patients with prediabetes and hypertension be treated with antihypertensive agents that include those that inhibit the renin–angiotensin system (RAS) – angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)—to the same blood pressure goal recommended for patients with overt diabetes, i.e. < 130/80 mmHg. This evidence concerns the gene ACE and hypertensive disorder.